Winton Group’s Iovance Biotherapeutics IOVA Stock Holding History

Winton Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$192K	Sell	46,200 -291,457	-86%	-$1.11M	0.01%	1024
2026 Q1	$1.19M	Buy	+337,657	New	+$1.08M	0.04%	497
2023 Q2	–	Sell	-18,929	Closed	-$116K	–	934
2023 Q1	$116K	Buy	18,929 +208	+1%	+$1.44K	0.01%	926
2022 Q4	$120K	Buy	18,721 +879	+5%	+$6.86K	0.01%	882
2022 Q3	$171K	Buy	+17,842	New	+$206K	0.01%	884
2022 Q2	–	Sell	-16,190	Closed	-$270K	–	1008
2022 Q1	$270K	Buy	16,190 +3,089	+24%	+$47.8K	0.01%	842
2021 Q4	$250K	Buy	+13,101	New	+$288K	0.02%	885
2021 Q1	–	Sell	-15,264	Closed	-$708K	–	1409
2020 Q4	$708K	Sell	15,264 -3,101	-17%	-$123K	0.05%	603
2020 Q3	$605K	Buy	+18,365	New	+$563K	0.02%	1032

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Winton Group's IOVA Position: Q2 2026 in Review

Winton Group reduced its Iovance Biotherapeutics (IOVA) stake by 86% in Q2 2026, selling an estimated $1.11M and leaving 46,200 shares worth $192K. The position accounts for 0.01% of the portfolio, ranked #1024.

Winton Group first reported a position in IOVA in Q3 2020 and has held it in 9 quarters since. The position peaked at $1.19M in Q1 2026. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Winton Group held 46,200 shares of Iovance Biotherapeutics worth $192K as of Q2 2026.
Winton Group sold 291,457 Iovance Biotherapeutics shares in Q2 2026, an estimated $1.11M.
Iovance Biotherapeutics made up 0.01% of Winton Group's portfolio in Q2 2026, its #1024 holding.
Winton Group first reported a position in Iovance Biotherapeutics in Q3 2020 and has held it in 9 quarters since.
Winton Group's Iovance Biotherapeutics position peaked at $1.19M in Q1 2026.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.